In the above article [Eaton JB, Peng J-H, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo Y-P, Steinlein O, and Lukas RJ (2003) Mol Pharmacol 64:1283-1294], Table 3 was incorrect due to printing errors. The corrected table appears below.⇓
Parameters for interactions of indicated drugs with hα4β2-nAChR in transfected SH-EP1 cells
Results presented in Figs. 6 to 9 and in Tables 1 and 2 are summarized. Functional EC50 values for agonists (column 2), functional IC50 values for antagonists (column 3; functional IC50 values given in parentheses for nicotine and suberyldicholine from fits to the self-inhibitory phase of agonist dose-response profiles for those drugs), and [3H]EBDN binding competition Ki values (column 4), all in micromolar, are expressed to allow comparisons between functional and radioligand binding competition affinities for the indicated ligands (drug; column 1). Also indicated (F/B; column 5) is the ratio between the functional EC50/IC50 and the binding competition Ki value (based on the IC50 value but corrected for the concentration of H-EBDN used in those assays and for the H-EBDN binding KD of 10 pM using the Cheng-Prusoff correction) for each ligand. The notations following the drug name for selected ligands indicate, from results shown in Fig. 9, functional antagonism actions as a noncompetitive inhibitor (N), a competitive inhibitor (C), or a mixed competitive/noncompetitive inhibitor (N/C).
We regret this error and apologize for any confusion or inconvenience it may have caused.
- The American Society for Pharmacology and Experimental Therapeutics